BlossomHill Therapeutics Inc

📅 Upcoming

🕒 Recent(90d)

News

• BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
  BlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…
  biospace · 8d ago
• Latigo IPO raises nearly $350M for pain drug development
  The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.
  biopharma_dive · 11d ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 11d ago
• Updated: BlossomHill, Latigo cap four-IPO week with combined $496M haul
  A cancer biotech vying for a piece of AstraZeneca's cancer territory and a pain specialist chasing Vertex's landmark non-opioid drug are capping an IPO-heavy week. BlossomHill Therapeutics and Lati…
  endpoints · 11d ago
• Cardiac drug developer Braveheart banks more than $382M in IPO
  Braveheart is one of five biotechnology firms that made plans to price an IPO this week. They could collectively raise more than $1 billion from public investors.
  biopharma_dive · 12d ago
• BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
  BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
  fiercebiotech · 15d ago
• Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
  In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
  fiercebiotech · 25d ago
• Pain drugmaker Latigo outlines plans to go public
  The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.
  biopharma_dive · 28d ago
• Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
  Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
  fiercebiotech · 29d ago
• Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
  Latigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.
  fiercebiotech · 1mo ago